CTCatch™ Clinical Applications in Pancreatic Cancer

1. Consult your physicians about CTCatch™ test.
2. Collect 7.5mL peripheral blood.
3. Analyze samples in Abnova Diagnostics Japan lab.
4. Generate your report in 7 days.
5. View test results under physician guidance.

CTC Liquid Biopsy for Pancreatic Cancer

Abnova Diagnostics Japan
CTCatch™ Test

Consult your physicians about CTCatch™ test.
Pancreatic Cancer

Pancreatic cancer is the twelfth most common cancer in the world (joint position with kidney cancer), with 338,000 new cases diagnosed in 2012. The early stages of this cancer do not usually produce symptoms, so the disease is generally advanced when it is diagnosed. The estimated 5-year prevalence of people in the world living with pancreatic cancer is 4.1 per 100,000. This cancer is almost always fatal, and is the seventh most common cause of death from cancer.

In contrast, CTCatch™ test can be helpful in diagnosis of metastatic pancreatic cancer, especially when primary tumor is small and difficult to detect, or tissue biopsy is limited to metastatic sites and primary lesion. Detection of circulating tumor cells (CTCs) in pancreatic cancer determines cancer cells shed from primary pancreatic tumor and other metastatic sites, but also allows dynamic sampling at multiple time periods during clinical course to early identify symptoms and determine treatments.

**Tissue Biopsy**
- Residual cancer cells
- Not repeatable
- Not real-time
- High false negative rate

**CTCatch™ Test**
- Non-invasive, blood sampling
- Repeatable
- Real-time and long-term monitoring
- Useful adjunct to tissue biopsy

Reference
1. World Cancer Research Fund International